Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
OTX015, Y-803
print preview
bookmark
share with colleague
General Information
Company
Mitsubishi Tanabe Pharma Corp.
Description
Synthetic small molecule inhibitor of BET bromodomain containing 2 (BRD2), BRD3 and BRD4
Molecular Target
Bromodomain containing 2 (BRD2)
;
Bromodomain containing 3 (BRD3)
Mechanism of Action
Latest Stage of Development
Phase I
Indication
Hematologic malignancies
Partner
Oncoethix S.A.
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy